Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EpiCblood

Financiado

Towards early cancer detection and tumor classification using epigenomic biomark...

Towards early cancer detection and tumor classification using epigenomic biomarkers in blood Early cancer detection could increase curative treatment and long-term survival. Dying cells release small DNA fragments wrapped around a core of histone proteins into the bloodstream, so-called circulating cell-free nucleosomes (... ver más

31/12/2028

LMU MUENCHEN

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-27

ERC-2023-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

LMU MUENCHEN

1.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EpiDetect Detecting epigenetic biomarkers in the blood for non-invasiv... 2M€ Cerrado

OR-HMC Assay for cancer diagnostics by quantification of 5hmC 150K€ Cerrado

MultiCloneSeq Single-Clone Multi-omics Sequencing for Cancer Diagnosis 150K€ Cerrado

ONCOTRACK OncoTrack - Methods for systematic next generation oncology... 31M€ Cerrado

EQC2018-004733-P ADQUISIÓN DE EQUIPO PARA IDENTIFICACIÓN Y RECUPERACIÓN DE CÉ... 171K€ Cerrado

EQC2021-006895-P Espectrómetro de masas para la medida multiparamétrica simu... 525K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2023-11-27
Fecha Fin: 2028-12-31

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Early cancer detection could increase curative treatment and long-term survival. Dying cells release small DNA fragments wrapped around a core of histone proteins into the bloodstream, so-called circulating cell-free nucleosomes (cf-nucleosomes). They carry DNA sequence information and histone modifications stable in blood, reflecting promising epigenomic disease biomarkers. But, the low proportion of cf-nucleosomes originating from cancerous cells versus the large background of nucleosomes arising from dying blood cells poses significant challenges for early cancer detection using circulating cf-nucleosomes. In EpiCblood, I will tackle these challenges and propose two complementary strategies to increase the number of cancer-signature cf-nucleosomes for cancer detection and tumor classification. In the first strategy, I will employ my previously developed synthetic histone modification readers to profile abundant histone modifications on cf-nucleosomes allowing me to seize up to 35 percent of the human genome non-invasively. I will prove this technology’s concept by detecting earlier stages of pancreatic cancer and simultaneously classifying molecular tumor subtypes. Furthermore, I hypothesize that tumorigenesis gives rise to cancer-specific genomic sites decorated with combinatorial histone marks, so-called bivalent regions, found explicitly in cancer and not in healthy adult cell types. In the second strategy, I will employ a computational pipeline to map cancer-specific bivalent sites across multiple cancer genomes. I will use my well-established combinatorial histone mark readers to test their diagnostic potential as cancer-specific biomarkers in blood plasma from healthy donors and cancer patients. My genomics expertise and proven technology provide an excellent basis for accomplishing the planned goals. EpiCblood will be a major step towards developing precise and rich liquid biopsy assays for multiple clinical applications in cancer management.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores